Abstract
The chemoattractant cytokines (chemokines) have been classified into 4 major subfamilies in relation to the position of the cysteine residues in their NH2 terminal portion. Interferon-γ inducible chemokines (CXCL9/Mig, CXCL10/IP-10, CXCL11/I-TAC), Strongly associated to Th1-me-diated immune responses, belong to the CXC sub-family. They represent an exception among chemokines in that they specifically interact with a single type of receptor, named CXCR3. A statisti-cally significant increase of CXCL10/IP-10 and CX-CL9/Mig expression, in thyroid tissue specimens obtained from subjects affected by Hashimoto’s thyroiditis and recent onset Graves’ disease has been reported. Furthermore, a statistically signif-icant increase in serumCXCL10/IP-10 levels has been found in newly diagnosed Graves’ patients when compared to healthy subjects as well as patients with long standing disease and a strong statistically significant inverse correlation between circulating CXCL10/IP-10 levels and disease dura-tion has been demonstrated. Similar findings have been obtained when Type 1 autoimmune diabetes affected patients have been taken into account. In conclusion, Such experiences have demonstrated an important role played by interferon-γ inducible CXC chemokines in the pathogenesis of glandular autoimmunity. In fact, it is reasonable to assume that glandular epithelial cells may modulate the autoimmune process at least in its initial phase, through the production of chemokines which induce migration of Th1 lymphocytes into the gland. Interferon-γ secretion by lymphocytes would, in turn, stimulate chemokines production by follicular cells, thus perpetuating the autoimmune cascade.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Zlotnik A., Yoshle O. Chemokines: a new classification system and their role in immunity. Immunity 2000, 12: 121–127.
Arenberg D.A., Polverini P.J., Kunkel S.L. et al. The role of CXC chemokines in the regulation of angiogenesis in non-small cell lung cancer. J. Leukoc. Biol. 1997, 62: 554–562.
Muller A., Homey B., Soto H. et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410: 50–56.
Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu. Rev. Immunol. 2000, 18: 217–242.
Cascieri M.A., Springer M.S. The chemokine/chemokine-receptor family: potential and progress for therapeutic intervention. Curr. Opin. Chem. Biol. 2000, 4: 420–427.
Romagnani P., Annunziato F., Lasagni L. et al. Cell cycle dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J. Clin. Invest. 2001, 107: 53–63.
Serio M. Interferon-γ induced chemochines:impact on metabolic and endocrine diseases. Endocrinol. Invest. 2001, 24: 2 (abstract).
Garciá-López M.A., Sancho D., Sánchez-Madrid F, Marazuela M. Thyrocytes from autoimmune thyroid disorders produce the chemokines IP-10 and Mig and attract CXCR3+ lymphocytes. J. Clin. Endocrinol. Metab. 2001, 86: 5008–5016.
Romagnani P., Lazzeri E., Lasagni L. et al. IP-10 and Mig production by glomerular cells in human proliferative glomerulonephritis and regulation by nitric oxide. J. Am. Soc. Nephrol. 2002, 13: 53–64.
Romagnani P, Rotondi M., Lazzeri E. et al. Expression of P-10/CXCL10 and Mig/CXCL9 in the thyroid and increased serum levels of IP-10/CXCL10 in the serum of subjects with recent onset Graves’ disease. Am. J. Pathol. 2002, 161: 195–206.
Romagnani S. The Th1/Th2 paradigm in disease. R.G. Sandes Company, Austin, Texas, 1996.
Aniszewski J.P., Valyasevi R.W., Bahn R.S. Relationship be-tween disease duration and predominant orbital T cell subset in Graves’ ophtalmopathy. J. Clin. Endocrinol. Metab. 2000, 85: 776–780.
Shimada A, Morimoto J., Kodama K. et al. Elevated serum P-10 levels observed in Type 1 diabetes. Diabetes Care 2001, 24: 510–515.
Nicoletti F., Conget I., Di Mauro M. et al. Serum concen trations of the interferon-gamma-inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed Type diabetes mellitus patients and subjects at risk of developing the disease. Diabetologia 2002, 45: 1107–1110.
Raz I., Elias D., Avron A, Tamir M, Metzger M., Cohen I.R. β-cell function in new onset type 1 diabetes and im-munomodulation with a heat shock protein peptide (DiaPep277): a randomized, double-blind, phase II trial. Lancet 2001, 358: 1749–1753.
Author information
Authors and Affiliations
Corresponding author
Additional information
An erratum to this article is available at http://dx.doi.org/10.1007/BF03345152.
Rights and permissions
About this article
Cite this article
Rotondi, M., Lazzeri, E., Romagnani, P. et al. Role for interferon-γ inducible chemokines in endocrine autoimmunity: An expanding field. J Endocrinol Invest 26, 177–180 (2003). https://doi.org/10.1007/BF03345149
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03345149